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Abstract
Background: In the rat brain, a single intracerebroventricular injection of neuraminidase from Clostridium
perfringens induces ependymal detachment and death. This injury occurs before the infiltration of inflammatory
blood cells; some reports implicate the complement system as a cause of these injuries. Here, we set out to test the
role of complement.
Methods: The assembly of the complement membrane attack complex on the ependymal epithelium of rats
injected with neuraminidase was analyzed by immunohistochemistry. Complement activation, triggered by
neuraminidase, and the participation of different activation pathways were analyzed by Western blot. In vitro
studies used primary cultures of ependymal cells and explants of the septal ventricular wall. In these models,
ependymal cells were exposed to neuraminidase in the presence or absence of complement, and their viability was
assessed by observing beating of cilia or by trypan blue staining. The role of complement in ependymal damage
induced by neuraminidase was analyzed in vivo in two rat models of complement blockade: systemic inhibition of
C5 by using a function blocking antibody and testing in C6-deficient rats.
Results: The complement membrane attack complex immunolocalized on the ependymal surface in rats injected
intracerebroventricularly with neuraminidase. C3 activation fragments were found in serum and cerebrospinal fluid
of rats treated with neuraminidase, suggesting that neuraminidase itself activates complement. In ventricular wall
explants and isolated ependymal cells, treatment with neuraminidase alone induced ependymal cell death;
however, the addition of complement caused increased cell death and disorganization of the ependymal
epithelium. In rats treated with anti-C5 and in C6-deficient rats, intracerebroventricular injection of neuraminidase
provoked reduced ependymal alterations compared to non-treated or control rats. Immunohistochemistry
confirmed the absence of membrane attack complex on the ependymal surfaces of neuraminidase-exposed rats
treated with anti-C5 or deficient in C6.
Conclusions: These results demonstrate that the complement system contributes to ependymal damage and
death caused by neuraminidase. However, neuraminidase alone can induce moderate ependymal damage without
the aid of complement.
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Background
The ependyma is a multiciliated cubic epithelium that
covers the ventricular cavities of the central nervous
system (CNS) in chordates. It contributes to the cerebro-
spinal fluid (CSF) flow through cilia beating, and serves as
a morphological and functional barrier between the CSF
and the CNS parenchyma, as it controls the movement of
molecules from one compartment to the other. Thus,
the ependyma regulates CSF composition [1–3]. The
ependymal cells are considered part of the subventricular
zone niche located in the lateral ventricles in the adult
brain [4] and contribute to neurogenesis by producing
regulatory factors [5]. Some authors have even proposed
that ependymal cells themselves could act as neural stem
cells in adults [6].
Therefore, the loss of the ependymal layer represents a
serious, and irreparable, injury to the CNS with conse-
quences for CSF homeostasis [7, 8]. Furthermore, the
absence of the ependymal barrier facilitates the access of
pathogens and inflammatory cells from the CSF to the
parenchyma. This could be related, in the long run, to
the development of demyelinating or neurodegenerative
disorders [9].
A relationship has been established between CSF
infection by viruses, particularly myxoviruses (mumps, in-
fluenza, and measles), and ependymal death. The latter
has also been linked to the development of hydrocephalus
[7, 10–13]. An association has also been reported between
viral infections during pregnancy or infancy and subse-
quent degenerative pathologies in the adult. Such is the
case for the Epstein-Barr virus (which causes infectious
mononucleosis) and multiple sclerosis [14, 15], influenza
virus infection during pregnancy and schizophrenia in the
adult offspring [16, 17], and measles infection and sub-
acute sclerosing panencephalitis [18, 19]. In most cases, it
is the inflammatory process following the infection that
directly causes the neurodegeneration [20]. The fact that
both ependymal loss and neurodegenerative disorders had
been associated with the same infectious agents indicates
that a relationship between these processes could exist.
It is conceivable that the ependymal loss caused by in-
fections might allow access to CNS parenchyma of the
infectious agent and the inflammatory cells, these being
responsible for the subsequent neurodegeneration [9].
For this reason, it is crucial to understand both the
mechanisms used by the infectious agents (virus and/or
bacteria) to destroy the ependymal lining, as well as the
inflammatory process that follows.
A single intracerebroventricular injection of Clostridium
perfringens neuraminidase (NA) within the lateral ventricle
of rats induces the massive detachment and death of
the ependymal cells, followed by acute inflammation in
ventricles and meninges and obstructive hydrocephalus
due to Sylvius aqueduct stenosis [21]. The ependymal
cell death occurs immediately after the injection and
prior to inflammation, indicating that it is caused by
the presence of NA in the CSF and not by inflammatory
cells. The NA catalyzed sialic acid removal from the
ependymal cell glycocalyx brings about ependymal
death by an unknown mechanism [21].
NA is an exo-glucosidase that removes terminal sialic
acid from glucidic chains, preferably those joined by α2–
3 (α2–3 > α2–8 = α2–6) linkages. In most glucidic chains
attached to proteins, galactose is the sub-terminal sugar
residue [22], which becomes exposed after NA action.
Thus, when NA acts on the ependymal lining, the sialic
acid cover is replaced by a galactose cover.
We hypothesize that NA directly provokes ependymal
cell death because (1) it removes the sialic acid protection
from the cell surface and (2) it activates the complement
system in the CSF. Both events lead to the deposition of
complement activation products, including the membrane
attack complex (MAC), onto the cellular surface resulting
in cell damage or death.
The complement system is a humoral innate defensive
mechanism formed of about 40 plasma- and membrane-
bound proteins that can be activated by three different
pathways: the classical pathway, which requires the
participation of immunoglobulins; the alternative pathway,
activated by “foreign” surfaces; and the lectin pathway,
initiated by certain sugars. All of them converge at a
common step, the cleavage of the C5 component into C5a
and C5b. This event triggers the assembly of factors C6,
C7, C8, and C9 that form the MAC on the target cells [23].
The above-mentioned hypothesis is based upon the
following facts:
1) All the components of the classical and alternative
complement pathways are present in the CSF to
provide protection to the CNS against infectious
agents, starting an inflammatory reaction and aiding
the removal of cellular debris [24–26].
2) Ependymal cells bear at their surface proteins that
regulate the complement system, such as CD55 and
CD59, which are upregulated upon infections like
meningitis [27]. This fact supports the capacity of
ependymal cells to modulate complement-mediated
injuries triggered by cerebral insults.
3) Sialic acid is abundant on the surface of ependymal
cells [21]; it protects ependymal cells by (i)
increasing factor H affinity, which inhibits the
activation of complement by the alternative pathway
and (ii) preventing the deposition of MAC [28, 29].
4) Sialic acid removal from human tumor cells and red
blood cells renders them vulnerable to alternative
pathway activation and the MAC [30, 31]. Similarly,
sialic acid in the bacteria lipopolysaccharides inhibits
complement attack and formation of MAC on
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bacterial cells, thus contributing to bacterial
virulence [32].
5) NA can directly activate the alternative complement
pathway, both in the fluid phase and on the cell
surface [33].
The aim of this work was to analyze to what extent
the complement system is responsible for the death of
ependymal cells induced by NA. Therefore, we studied
in an in vivo model the formation of MAC deposits onto
the cells damaged by NA and the activation of the different
complement pathways in the NA-injected ventricle. We
also confirmed in vitro the ability of NA to directly activate
complement. Finally, we tested the effects of absence
or inhibition of MAC formation in vivo on the death
of ependymal cells upon treatment with NA.
Methods
Animals
Adult male Wistar rats (Charles River Laboratories,
Barcelona, Spain) (body weight 250–300 g) were used
in this study. In addition, a strain of rats deficient in
the C6 component of complement that is unable to
generate membrane attack complex [34, 35] was used.
All animals were housed under a 12-h light/dark cycle
with food and water available ad libitum. Animal proce-
dures were performed according to the European Union
(86/609/EEC) and Spanish (RD 1201/2005) legislations.
Animal care and experimental procedures were approved
by the Animal Experimentation Ethics Committee of the
University of Málaga (ref. number 2012-0013).
Intracerebroventricular injection
The animals were anesthetized with 2,2,2-tribromoethanol
(0.2 g/kg bw, Fluka Chemika) and positioned in a stereo-
taxic frame. NA from C. perfringens (Roche Diagnostics,
11 585 886 001) dissolved in 0.9 % sterile saline (25 mU/μl)
was administrated by stereotaxic surgery into the right
lateral cerebral ventricle (intracerebroventricular (icv)).
The coordinates from Bregma used were antero-posterior
−0.5 mm, medio-lateral −1.4 mm, and dorso-ventral
−3.5 mm. A single dose of 500 mU (20 μl) of NA was
injected with the aid of a pump at a rate of 2 μl/min dur-
ing 10 min. Control rats were injected with saline or with
heat-inactivated NA [36]. Some animals were sacrificed
immediately after NA injection (time 0 h), and the rest
were recovered from anesthesia and sacrificed at 2 h, 4 h,
12 h, 24 h, 2 days, 4 days, 7 days, 15 days, 30 day,
3 months, and 6 months after the administration of NA.
Inhibition of the complement component C5
In order to obtain both systemic and ventricular inhibition
of complement component C5, a strategy consisting
of the injection of a blocking monoclonal anti-rat C5
monoclonal antibody (C5-inh; clone 18A10, Alexion
Pharmaceuticals Inc. [37, 38]) was employed. The treat-
ment followed published protocols [39]; an initial intraven-
ous injection of the antibody (20 mg/kg bw) was followed
6 h later by an intraperitoneal injection of the same anti-
body (10 mg/kg bw). According to the published data, this
protocol achieved a 50–60 % inhibition of C5 activity for
up to 12 h after the first injection. The highest inhibition
occurs approximately 1 h after the second injection. At this
time of maximal systemic inhibition, the antibody was also
injected icv to obtain a ventricular inhibition of C5. The in-
hibitor was icv injected along with NA (20 μl of a mixture
of NA 25 mU/μl and C5-inh 0.38 μg/μl) following the
same parameters outlined above.
Obtaining and culture of ventricular wall explants
The brains of the euthanized rats were removed, and
ventricular wall explants were obtained following the
protocol described elsewhere [40]. The explants were
washed in DMEM-F12 medium (Gibco) and incubated for
2 h (37 °C, 5 % CO2) in the same medium supplemented
or not with neuraminidase (5 mU/μl) or rat serum (50 %
v/v) as a source of complement factors. Five replicates of
each experimental situation were performed. The explants
were finally fixed by immersion in Bouin’s fixative for 24 h
and processed for histological sectioning.
Obtaining and culture of isolated ependymal cells
Ventricular wall explants were used in order to obtain
pure isolated ependymal cells [40]. Briefly, the explants
were sequentially incubated in (1) HBSS without calcium
and magnesium (Gibco); (2) TrypLE Express ™ solution
(Gibco); (3) αMEM (Gibco) supplemented with 0.2 %
Pluronic F-127 (Sigma), 0.3 % D-glucose (Sigma), and
0.01 M HEPES (Sigma; for details of incubation times
and temperatures, see [40]). During the last incubation, the
cells detach from the explant and are released to the
medium. They were then harvested by centrifugation
(300×g, 10 min) and resuspended in supplemented αMEM.
Isolated ependymal cells were placed in individual
wells in a final volume of 1.6 ml and at a density of 104
cells/ml in αMEM with D-glucose and HEPES. Accord-
ing to each experimental situation, the medium was sup-
plemented with NA (5 mU/μl), serum (50 % v/v) as a
source of complement factors, and/or C5-inh (0.4 μg/μl;
Alexion Pharmaceuticals Inc.).
Cell viability was then assessed by trypan blue staining.
Cell samples (200 μl, about 2000 cells) from each well
were taken at different times: 0 min (before adding the
treatments), 5, 10, 20, 30, 40, 50, and 60 min. Each 200-
μl cell sample was mixed with 200 μl of a 0.4 % trypan
blue solution (Sigma), incubated (5 min), and centri-
fuged (500×g, 5 min). The cell pellet obtained was resus-
pended in 100 μl 4 % of paraformaldehyde fixative and
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placed on a slide for counting under an optical micro-
scope. The experiment was performed in triplicate.
Histological procedures
The animals were anesthetized with 2,2,2-tribromoetha-
nol and transcardially perfused with saline followed by
Bouin’s fixative. Brains were removed and immersed in
the same fixative for 24 h at room temperature (RT) and
later embedded in paraffin wax. Cultured explants were
fixed by immersion in Bouin’s fixative for 24 h and later
embedded in paraffin as well. Seven-micrometer sections
were obtained from each brain/explant and mounted on
poly-L-lysine-treated slides. Series of sections along the
brain region of interest (from bregma −0.3 to −1.2 mm
approximately) were obtained. Some brains were har-
vested unfixed to obtain frozen sections. Fresh brains from
the euthanized rats were removed, washed in 0.1 M
phosphate-buffered saline (PBS), embedded in Tissue-Tek
OCT™ Compound (Sakura), and frozen on a metal plate
cooled with liquid nitrogen. Ten-micrometer sections
were obtained with a cryostat and immediately fixed in
cold acetone for 10 min, as described [41] for complement
factor preservation. Hematoxylin-eosin staining was ap-
plied to counterstain the sections.
Lectin binding
The peanut (Arachis hypogaea) agglutinin (PNA, Vector)
was chosen for its exclusive affinity for terminal residues
of galactose, which are the sub-terminal sugar residues
in complex-type glycoproteins. After the removal of
terminal sialic acid, galactose is exposed as a terminal
residue, and the PNA binding sites arise. To check for the
removal of sialic acid by the action of NA, the sections
from the explants were incubated in 3 μg/ml peroxidase-
labeled PNA in 0.1 M PBS for 1 h at RT. The peroxidase
activity was detected with 0.1 M PBS containing
0.05 % diaminobenzidine (DAB, Sigma) and 0.03 % hydro-
gen peroxide (Merck).
Immunohistochemistry
Immunohistochemistry was carried out on deparaffi-
nized tissue sections using either immunoperoxidase or
immunofluorescence techniques. The primary antibodies
used were rabbit anti-rat C5b-9 (1:200, Abcam, ab55811);
rabbit anti-rat C9 (1:100, provided by Prof. B. P. Morgan,
Cardiff University); and mouse anti-rat vimentin (1:1000,
Sigma, V6630). The secondary antibodies used were
biotinylated goat anti-rabbit IgG (H+L) (1:1000, Pierce,
31820); Alexa fluor® 488 goat anti-rabbit IgG (H+L)
(1:1000, Molecular Probes, A11070); Alexa fluor® 594
donkey anti-mouse IgG (H+L) (1:1000, Molecular Probes,
A21203). All antibodies were diluted with PBT buffer
(0.3 % bovine serum albumin, 0.3 % Triton X-100 in PBS
pH 7.3). The primary antibodies were incubated overnight
at RT. The secondary antibodies were incubated for
60 min at RT. Negative controls for the immunostaining
consisted in equivalent sections are subjected to the same
protocol but omitting the primary antibody.
Prior to the overnight incubation with the primary
antibody, the sections stained with the immunoperoxidase
procedure were incubated in 3 % hydrogen peroxide
and 10 % methanol in phosphate buffer (PB) 0.1 M to
quench endogenous peroxidase activity. In such sections,
biotinylated secondary antibody was used, along with the
avidin-biotin-complex (ABC) amplification method. The
ABC reagent was prepared according to the manufac-
turer’s instructions (Thermo Fisher Scientific) and incu-
bated for 30 min. Peroxidase activity was revealed with
0.05 % DAB and 0.03 % hydrogen peroxide. All the incu-
bations were performed in a moist chamber at RT.
For immunofluorescence, Alexa fluor® 488- or Alexa
fluor® 594-conjugated secondary antibodies were used,
and the DNA binding dye 4,6-diamidine-2-phenylindole
dihydrochloride (DAPI) (0.1 μg/ml) was added to the
secondary antibody solution. Coverslides were mounted
with buffered glycerol containing 10 % of the anti-fading
agent Mowiol 4-88 (Calbiochem/EMD Chemicals). The
sections were then observed under a confocal microscope
(Leica, SP5 II).
Obtaining and activation of serum and CSF
Rat blood was drawn by puncture of the tail vein, under
sterile conditions and kept cold to preserve the activity
of the complement system. Once coagulated, serum was
prepared by centrifugation (1500×g, 10 min, 4 °C).
To obtain CSF, anesthetized rats were placed in a
stereotaxic apparatus with the head tilted at an angle of
75° to the dorsal spine. A needle connected to a cannula
was introduced through the cranium-atlas joint into the
cisterna magna, at a depth of about 7 mm. CSF was re-
moved with a pump (KD Scientific, model KDS-210-CE)
connected to the syringe at a rate of 2 μl/min in 20 μl
fractions, with pauses of 5 min between fractions, until a
total volume of 80–100 μl was obtained. The samples
were immediately placed in ice to preserve complement
activity. We checked that the CSF was clear and not
contaminated with blood. Extracted CSF was collected
in a sterile tube and stored at −80 °C until use.
Obtaining of ependymal epithelium extracts
The extracts were obtained from the explants of the
ependymal wall in order to analyze the presence of
certain proteins by Western blot. The explants obtained
were weighed, homogenized in ice, and 30 μl of protein
extraction buffer (Complete Mini (Roche) in 20 mM
Tris-HCl, 100 mM NaCl, 0.2 % Triton X-100) were added
per milligram of tissue. Sonication was applied to further
homogenize. The homogenate was then centrifuged
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(5600×g, 5 min, 4 °C) and the supernatant recovered.
Finally the total protein concentration was determined by
the bicinchoninic acid method (BCA Protein Assay Kit,
Pierce), prior to analysis in Western blot.
Immunoprecipitation
In order to enrich the samples for subsequent detection
by Western blot of the proteins C1q and mannose-
binding lectin (MBL), immunoprecipitation was applied
to the serum and ependymal epithelium extracts. The
procedure was based on that suggested by the manufac-
turer of the Mouse TrueBlot® Set IP-Beads kit (Rockland).
Briefly, after pre-washing of the beads and the pre-clearing
of the samples, to each aliquot (500 μl of serum or extract
diluted 1 mg/ml in PBS) was added 3 μg of primary anti-
body (mouse anti-C1q, Abcam 71940 or mouse anti-MBL,
Abcam 23461) and 50 μl of pre-washed beads. The samples
were incubated 2 h at 4 °C on rotation, and then centri-
fuged (2500×g, 3 min, 4 °C). The supernatant was removed
and the beads were washed three times with 500 μl of RIPA
buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 %
NP-40, and 0.25 % sodium deoxycholate). After the last
wash, the beads were resuspended in 50 μl of gel loading
buffer, heated at 95 °C for 10 min, and centrifuged
(10,000×g, 5 min), and the supernatant obtained was sub-
jected to polyacrylamide gel electrophoresis (PAGE).
Western blot
Western blot was used to identify the deposition of C1q
and MBL on the ependyma of NA-injected rats. For this
purpose, the serum and ependyma samples were sub-
jected to immunoprecipitation as described above.
On the other hand, the activation of complement in
serum and CSF samples was analyzed by monitoring the
fragmentation of C3 by Western blot. In this case, serum
and CSF 50 μl samples were incubated with 5 μl of zymo-
san 0.1 g/ml (positive control of complement activation),
5 μl of NA (50 mU/μl), or 5 μl of 0.9 % saline (negative
control of complement activation) for 1 h at 37 °C. After-
wards, they were centrifuged (9000×g, 10 min), and the
supernatant was recovered for PAGE.
The protein samples mentioned above were resolved
in 7.5 % SDS-PAGE (for the detection of C3) or 15 %
SDS-PAGE (for the detection of C1q and MBL) in the
presence of 2-β-mercaptoethanol (reducing conditions).
After electrophoresis, the proteins were transferred to a
PVDF membrane. The membranes were blocked with 5 %
skimmed milk and 1 % Tween-20 in PBS and incubated
overnight at RT with the primary antibodies mouse anti-
rat C3 (1:140, C3.30, Prof. B. P. Morgan, Cardiff Univer-
sity); rabbit anti-C1q (1:100, Hycult, HP8021); and mouse
anti-MBL (1:500, Abcam, 23461). As a negative control of
the primary antibody binding, a membrane corresponding
to a serum sample was treated alike but excluding
the primary antibody. The corresponding horseradish
peroxidase-conjugated secondary antibody (anti-mouse
TrueBlot®, 1:1500, Rockland, 18-8817-31; anti-rabbit
IgG, 1:1000, Sigma, A8275) was probed for 1 h at RT,
and detection of the antibody binding was determined
by chemiluminescence (Clarity™ Western ECL, Bio-Rad).
The chemiluminescence was recorded using a camera
Molecular Imager (Bio-Rad, ChemiDoc™ XRS+) and
Image Lab 4.0 (Bio-Rad) software.
Quantification of ependymal disruption
In order to quantify the severity and the extension of
the ependymal alterations, the percentage of intact, dam-
aged, and disrupted ependyma was measured on histo-
logical sections immunostained with anti-vimentin. Four
different experimental situations were analyzed: (i) sham-
operated wild-type rats, (ii) NA-injected wild-type rats,
(iii) NA-injected C5-inhibitor-treated wild-type rats, and
(iv) NA-injected C6-deficient rats. All animals were sacri-
ficed 2 h post-injection of NA. Three rats from each ex-
perimental situation were used. The percentage of intact,
damaged, and disrupted ependyma was measured on three
histological sections from each animal. The image analysis
software ImageJ (NIH) was used.
Statistical analysis
Differences between the percentage of living cells in the
different treatments were evaluated by ANOVA (signifi-
cance level of 0.05), followed by a Tukey’s post hoc test
with a level of significance of 0.05. The values measured
at time 0 were considered 100 %. The software SPSS®
Statistics 20 (IBM®) was used for this analysis.
Results
Membrane attack complex deposition onto ependymal
cells of NA-treated rats
The initial approach to investigate the potential role of
the complement system in ependymal cell death caused
by icv injected NA was to localize the MAC on the ap-
ical surface of the ependymal cells. This complex is com-
posed of the proteins C5b, C6, C7, C8, and several units
of C9 [42]. The immunocytolocalization of MAC was
performed by using two different antibodies which rec-
ognized, respectively: (i) an epitope of C5b-9 not present
in non-polymerized fragments and (ii) an epitope of C9
located in the polymer forming the transmembrane pore
[43] (see “Methods”).
Anti-C5b-9 labeled the apical membrane and cytoplasm
of most ependymal cells in the NA-injected ventricle
(2 h after injection) (Fig. 1a, c), a staining that was absent in
the contralateral non-injected ventricle (Fig. 1b, d). C5b-9-
positive ependymal cells presented an irregular shape and
seemed to be detached from the ventricular wall (Fig. 1c),
compared to the ependymal cells in the contralateral
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ventricle which kept a normal epithelial morphology
(Fig. 1b, d). A similar result was obtained with anti-C9 anti-
body. Double immunofluorescence showed a positive im-
munostaining at the apical surface and cilia of ependymal
cells only in the injected ventricle (Fig. 1e, g), but not in the
contralateral one or in non-injected rats (Fig. 1f).
NA activates complement component C3 in vitro
Western blot is a sensitive technique that test the activa-
tion of the complement system in vitro. C3 gives rise to
several fragments during its activation, deactivation, and
degradation process [44, 45] (Fig. 2a). An anti-C3 mono-
clonal antibody recognizing C3 α chain (113 kDa) before
activation, and the iC3b α’ chain fragment (62.5 kDa)
generated after activation [46], was used in immunoblot
to investigate whether NA was able to induce the activa-
tion of complement in serum and CSF samples. When
serum or CSF samples were incubated with NA, the
iC3b α’ fragment was formed (Fig. 2b, lanes “NA/37 °C”),
also seen when the samples (blood serum or CSF) were in-
cubated with zymosan, a complement activator used as a
positive control in this experiment (Fig. 2b, lanes “Zym/
37 °C”). In conditions where complement was not acti-
vated, the iC3b α’ fragment was not observed (Fig. 2b,
lanes “NaCl/4 °C”). We did observe some activation (pres-
ence of iC3b α’ fragment) in samples without NA but in-
cubated at 37 °C (Fig. 2b, lanes “NaCl/37 °C”), compared
to the same samples maintained at 4 °C. We infer that this
is due to auto-activation of complement and was always
less than the activation triggered by NA (Fig. 2b, lanes
“NA/37 °C”).
Identification of the complement pathways activated
by NA
The initiation of the classical pathway of complement is
mediated by the binding of C1 to IgM or IgG molecules
previously bound to their antigens. The desialylation of
the ependymal epithelium by NA might expose epitopes
recognized by immunoglobulins, therefore allowing the
assembly of C1 and triggering the classical pathway acti-
vation. We first tried to detect immunoglobulin deposits
on the ependymal cells of the rats injected with NA by
immunohistochemistry using anti-IgG antibodies. How-
ever, no IgG deposits were detected (not shown).
Next, the presence of C1q (a C1 complex component)
on the ependyma of the NA-injected rats was searched by
immunohistochemistry (not shown) and by Western blot
(Fig. 3a). C1q was not detected in any case. A 26-kDa
band corresponding to the expected molecular weight of
C1q A chain was detected in the normal rat serum sam-
ples used as the positive control (Fig. 3a, lane “C+”).
The sialidase activity of NA on ependymal cells results
in the exposure of galactose residues in N-linked glyco-
proteins [47]. These residues pose a potential binding
site for MBL, which activates the complement lectin
pathway. The presence of MBL on the ependymal sur-
face of the NA-injected rats compared to non-injected
control rats was analyzed by immunohistochemistry and
immunoblot. The anti-MBL antibody did not show the
presence of MBL on the ependymal surface by immuno-
histochemistry (not shown) nor in the ependyma ex-
tracts by Western blot (Fig. 3b). However, a band of
25 kDa corresponding to the MBL monomer was ob-
served in the rat serum samples used as the positive






Fig. 1 Detection of C5b-9 complex and C9 on the ependymal
epithelium of rats injected with NA. a–d Immunohistochemistry
using anti-C5b-9 showing the injected (a, c) and the contralateral
(b, d) ventricles. Two hours after NA injection, a positive label could be
observed on the ependymal surface of the injected ventricle (c), which
was absent in the contralateral one (d). e–g Cryostat 10-μm sections
double labeled with anti-C9 (green), anti-vimentin (red), and the nuclear
stain DAPI (blue). The ependymal cells of the injected ventricle showed
C9 deposits on the apical surface and cilia (e and g) that were
not present in the contralateral ventricle (f). LV lateral ventricle, DAPI,
4,6-diamidine-2-phenylindole dihydrochloride, Ep ependyma, NP
nervous parenchyma, CP choroid plexus, Str striatum, Sp septum.
(Arrows) Damaged cells
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Fig. 2 Neuraminidase induces C3 activation in vitro. a Scheme showing the activation, deactivation, and degradation of the complement factor
C3, based on [44, 45]. The anti-C3 antibody used for the immunoblot detects C3 α chain (113 kDa) before activation, and the iC3b α’ chain fragment
(62.5 kDa) generated after activation [46]. b Blood serum andcerebrospinal fluid (CSF) samples were used as the source of factor C3. They were
incubated with NA at 37 °C for 1 h (NA/37 °C), and then analyzed by immunoblot with anti-C3. Controls included: incubation in saline (NaCl) without
NA, both at 37 °C (NaCl/37 °C) and at 4 °C (NaCl/4 °C); a positive control of complement activation with zymosan (Zym/37 °C). Complement activation
correlates with fading of the C3 α band and concurrent appearance of iC3b α’ band. As expected, activation occurred in the positive controls
(Zym/37 °C) but not in the negative controls (NA/4 °C), both in serum and CSF samples. NA was also able to activate complement (NA/37 °C),
although not as much as zymosan, as the appearance of the iC3b α’ band is delayed. A partial activation was detected in the negative control
NaCl/37 °C, which can be ascribed to auto-activation of complement when it is maintained for 1 h at 37 °C. The specificity of the anti-C3 antibody
was proved by omitting the primary antibody during the immunoblot procedure (1st Ab bypass)
A
B
Fig. 3 Western blot detection of C1q and MBL in ependymal wall extracts. Protein extracts were prepared from the lateral wall of rats injected
with NA (R4–R6) and non-injected control rats (R1-R3). In order to increase the amount of target proteins (C1q and MBL) loaded in the gel, they
were immunoprecipitated from the extracts prior to the Western blot. Neither C1q (a) nor MBL (b) were detected in ependymal wall extracts,
regardless of the treatment with NA. Positive controls (C+) consisted in rat serum samples are subjected to the same procedure; the specificity of
the antibodies was checked by omitting the primary antibodies (1st Ab bypass)
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The complement system enhances NA-induced
ependymal cell damage in vitro
Ventricular wall explants were used to determine the
effect of NA on ependymal cells in the presence or
absence of complement. Cell viability was evaluated by
monitoring the ciliary movement at different times during
a 2-h period. Serum was used as a source of complement.
As shown in Table 1, ciliary movement was unaltered in
control explants incubated in culture medium (CM) as
well as in explants incubated in the presence of comple-
ment (CM + serum). However, cilia beating decreased after
1 h incubation with NA, either in the presence (CM + NA
+ serum) or absence (CM + NA) of complement.
To further analyze the results of the previous experi-
ment, the explants were fixed for histological evaluation.
The PNA lectin was used to confirm the sialidase action
of NA, and anti-vimentin immunohistochemistry to con-
firm the presence of ependymal cells in the explants. All
NA-treated explants were PNA-positive (Fig. 4f, l), con-
firming sialic acid removal. The hematoxylin-eosin stain-
ing revealed that explants incubated with culture
medium alone (CM, Fig. 4a–c) displayed an unaltered
ependymal cell layer with cells that were slightly eosino-
philic. Similar results were observed in the explants
treated with culture medium and complement (CM +
serum, Fig. 4g–i). However, the ependymal cells in the ex-
plants incubated with NA (CM + NA, Fig. 4d–f ) showed
signs of cell damage, such as a smaller cytoplasm and pyc-
notic nuclei. When complement was added in addition to
NA (CM + NA + serum, Fig. 4j–l), the ependymal cells
lost lateral cell-cell contacts and, therefore, the ependymal
epithelium appeared disorganized and displayed occa-
sional discontinuities. Hence, the experimental condition
CM + NA + serum was the one causing most damage,
which suggests that serum and NA acted synergistically to
harm ependymal cells.
A similar experimental design was performed but in
this case using a primary culture of pure ependymal cells
obtained from adult rats [40]. Viability of ependymal
cells was assessed with the vital stain trypan blue. The
number of viable ependymal cells at the beginning of the
experiment was considered as 100 %. Viability was mea-
sured at different time points after the addition of NA
and/or serum (Fig. 5). Viability decreased with time in
all culture conditions, but the addition of NA further re-
duced it, and this loss of viability was further accelerated
when serum was also present. In this condition (NA +
serum) viability dropped to 39.6 ± 3.5 % in just 30 min.
The addition of a complement inhibitor (C5-inh) partially
prevented this decrease in viability (64.0 ± 4.9 %), demon-
strating that complement present in serum is responsible
for the drop in viability.
C5 inhibition in NA-treated rats does not prevent
ependymal damage but decreases ependymal disruption
The proteolysis of the complement factor C5 yields the
fragment C5b, which is the first component responsible
for the initiation of the formation of MAC. Therefore,
C5 proteolysis is an essential step for MAC assembly [23].
It has been demonstrated that the systemic inhibition of
C5 proteolysis by treatment with anti-C5 antibodies
impedes the formation of MAC [37, 38].
To test the participation of MAC in the ependymal cell
death due to NA, the rats were systemically and ventricu-
larly inhibited with anti-C5 and then treated with an icv
injection of NA. Histological study of the ependymal epi-
thelium 2 h after the injection of NA revealed alterations
of ependymal cells, which acquired a flattened shape and
pycnotic nucleus. However, the ependymal epithelium was
not seriously disrupted (Fig. 6b; Fig. 8a; 11.3 ± 2.4 % dis-
rupted ependyma). In contrast, epithelial integrity was lost
in rats treated with NA without C5 inhibition (Fig. 6c;
Fig. 8a; 53.5 ± 8.5 disrupted ependyma). The ependymal
cells in the contralateral ventricle of NA-treated rats ap-
peared unaffected, as did those in rats treated with anti-
C5 but not injected with NA (Fig. 6a). The immunohisto-
chemical analysis with anti-C5b-9 showed the presence of
MAC deposits on the surface of the damaged ependyma;
MAC deposits were less prominent in the C5-inhibited
rats (Fig. 6e–f ).
NA-induced ependymal cell disruption is reduced in
C6−/− rats
In C6−/− rats the complement factor C6 is absent; hence,
MAC assembly is not possible. The ependymal cells of
the C6-deficient rats injected with NA displayed some
morphological alterations (arrows in Fig. 7b) but only a
minor disorganization of the epithelium (arrowhead in
Fig. 7b; Fig. 8a, 7.1 ± 3.2 % disrupted ependyma), com-
pared to NA-injected wild-type rats, where the epithe-
lium was markedly disrupted (arrowheads in Fig. 7c;
Fig. 8a; 53.5 ± 8.5 % disrupted ependyma). C5b-9 de-
posits were present on the ependyma of wild-type NA-
injected rats but, as expected, they were not detected
on the damaged ependyma of C6−/− mutant rats (Fig. 7e–f),
suggesting that MAC assembly is a major contributor
to but is not the sole cause of ependymal injury triggered
by NA.
Table 1 Number of explants showing cilia movement, out of
five explants per condition
Culture media Pre 0 h 1 h 2 h
CM 5 5 5 5
CM + NA 5 5 2 0
CM + serum 5 5 5 5
CM + NA + serum 5 5 3 1





Fig. 4 In vitro effects of NA and complement on the ependymal epithelium. Explants from the septal side of the lateral ventricle wall were
placed in culture and treated with NA and/or complement for 2 h. Rat serum was used as a source of complement. The ependyma in the
explants was then evaluated by histology. Anti-vimentin allowed the location of the ependyma in the explants (a, d, g, j). The squared regions are
those magnified in the hematoxylin-eosin staining (b, e, h, k). The sialic acid removal by NA was confirmed by binding of the lectin PNA (peanut
agglutinin; c, f, i, l). Ependymal damage occurred in explants treated with NA (e, k) and was worsened by the presence of serum (k). The concurrence
of NA and serum resulted in the loss of epithelium integrity, where gaps could be seen (arrowheads in l). Serum alone did not produce such damage (e).
CM culture medium, NA neuraminidase, Ep ependyma, NP nervous parenchyma. (Arrows) Damaged ependymal cells
A
B C
Fig. 5 In vitro effects of NA and complement on ependymal cell viability. Pure ependymal cells were isolated from adult rats and placed in
culture in the presence of NA and/or complement. Rat serum was used as a source of complement. a, b The viability of cells was monitored by
the exclusion of trypan blue stain; the living ependymal cells excluded the dye (a) while the dead cells stained blue (b). Arrows point to the cilia.
c The graph shows the percentage of live cells at different time points relative to living cells at time zero. The data are mean ± SEM of three
independent experiments. In the presence of NA and serum, there was a steep decline of the viability as soon as 10 min after the start of the
exposure, which continued dropping up to 40 % survival after 30 min. A milder decline in viability was also observed in cells treated with NA
alone with no serum. The involvement of the complement in facilitating NA-induced cell death was tested by using a complement blocking
antibody (C5-inh), which completely reversed the survival rate to the values obtained with NA alone. CM culture medium, NA neuraminidase,
C5-inh C5 inhibitor; *P < 0.05; **P < 0.01 compared to the control CM
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Discussion
A single icv injection of NA in the lateral ventricle of
rats results in the death of ependymal cells within 1 h
after the injection, followed by long-term hydrocephalus
[21]. This method of causing a lesion to the ependyma
has been used here and by other authors [47–50], ren-
dering similar outcomes with respect to ependymal de-
struction and the subsequent inflammatory reaction [9].
Despite the long history of the use of this model, the
precise mechanism of ependymal cell death after the re-
moval of sialic acid by NA is unknown. Ependymal death
occurs immediately after injection of NA and prior to
inflammatory cell infiltration. Therefore, inflammation
does not seem to be responsible for the observed cell
death, and a more direct action of NA should be con-
sidered. Several lines of evidence support a role for the
complement system: (i) the components of the comple-
ment system are present in the CSF [24–26] (ii) cells
deprived of sialic acid at their surface are more vulner-
able to complement attack [29, 31, 51]; and (iii) the
complement system can be activated by NA [33].
Hence, this study was designed to test the involvement
of the complement system on the death of ependymal
cells induced by NA.
Neuraminidase activates the alternative pathway of
complement and induces MAC deposition onto
ependymal epithelium
Immunohistochemistry demonstrated the presence of
MAC on the surface of the ependyma 2 h after the injec-
tion of NA. It is known that several cell types in the ner-
vous system can produce proteins of the complement
system [25, 52–54]. However, we can rule out that the
observed staining of ependymal cells is a result of syn-
thesis of C9 because (i) the antibodies used are specific
for the activated/polymerized forms of the proteins and
(ii) the label was more intense in those cells that ap-
peared more damaged. The ependymal identity of the
labeled cells could be established by their location,
morphology, and the presence of a tuft of cilia. Also,
C9 staining colocalized with vimentin, an intermediate
filament expressed by ependymal cells.
The activation of complement that promotes MAC as-
sembly onto the ependyma could be ascribed to (1) the
A B C
D E F
Fig. 6 Effect of NA on the ependyma of rats under systemic inhibition of C5. A group of rats were treated with a monoclonal antibody for the
systemic inhibition of C5. Some of them were icv injected with NA (C5-inh + NA; b, e) while others were not injected to serve as controls (C5-inh;
a, d). The control group for NA-dependent ependymal damage was injected with NA but not systemically inhibited (NA; c, f). The ependyma of
the injected ventricle was histologically evaluated, and the formation of the complement complex C5b-9 (MAC) studied by immunohistochemistry.
In the rats under systemic inhibition of C5, NA produced some damage to the ependymal epithelium; the cells appeared flattened and presented a
condensed pycnotic nucleus (b). However, the deposits of MAC were modest (e). These changes were mild compared to those provoked by NA in
non-inhibited rats (c), where the ependymal epithelium was disrupted and MAC deposits were conspicuous (f). Rats C5 inhibited but not injected with
NA showed an unaltered ependyma (a), and no MAC deposits at all (b). LV lateral ventricle, Ep ependyma, NP nervous parenchyma
A B C
D E F
Fig. 7 Effect of NA on the ependyma of C6-deficient rats. The damage caused by icv-injected NA on the ependyma was studied in a strain of rats
deficient for the complement factor C6 (b, e) 2 h after the injection of NA. Normal wild-type (WT) rats served as control for the NA-induced ependymal
damage (c, f). The formation of MAC deposits was evaluated by immunohistochemistry (d–f). The injection of NA did not induce MAC assembly onto
the ependyma of C6−/− rats (e). However, some ependymal cells presented a slightly condensed nucleus (arrows in b), while the epithelium appeared
with some minor disruptions (arrowhead in b) compared to that of control wild-type rats. These changes were minor compared to those observed in
wild-type rats treated with NA (c), where the epithelium appeared disorganized (arrowheads in c), and MAC deposits were abundant (arrows in e).
Ventricular walls from non-injected C6-/- rats (a and d) did not display any anomaly and were comparable to non-injected WT rats (data not shown).
LV lateral ventricle, Ep ependyma, NP nervous parenchyma, H-E hematoxylin and eosin staining
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direct action of NA on complement factors present in
the CSF and/or (2) the suppression of the regulatory fac-
tors that restrict complement activation, such as surface
sialic acid [31], factor H [29], or CD59 [55, 56]. Sialic
acid residues present in the bacterial capsule polysaccha-
rides represent a virulence factor, as they help to evade
complement activation and formation of MAC [32].
Also, it has been reported that sialic acid removal from
the surface of human cancer cells, red blood cells, and
other cell types makes them more prone to MAC depos-
ition [29, 31, 51]. Factor H is a soluble factor that binds
to sialic acid in cell membranes [29]. It inhibits the
formation of C3/C5 convertase complexes and arrests
the amplification of the activation signal. Factor H effect-
iveness is considerably decreased when the target cell sur-
face is devoid of sialic acid [55, 57, 58]. CD59 is a
complement activation inhibitor which prevents the for-
mation of MAC by interacting with C5b 8 and blocks C9
polymerization [55, 56]. CD59 itself bears sialic acid, so
NA could jeopardize CD59 inhibitory action. Although it
has been shown that sialic acid removal by NA does not
affect CD59 function in erythrocyte membranes [59],
this fact has not been tested in CNS cells. In the present
report, neither the factor H nor CD59 was analyzed in
ependymal cells of NA-injected rats, which would be of
interest in future works.
Western blot analysis revealed the presence of frag-
ments resulting from the activation of C3 in CSF and
serum samples exposed to NA. This could be the result
of the action of NA on C3 directly or on other factors
involved in the formation of soluble C3 convertase
complexes. Although the incubation of serum and CSF
samples was carried out in the absence of cell membranes,
it has been shown that the assembly of C3 convertase
complexes is feasible even if no membrane attachment
occurs [60, 61].
On the other hand, no deposits of C1q or MBL could be
detected on the ependymal surface of the NA-injected
ventricle, neither by immunohistochemistry (not shown)
nor by Western blot. All the above evidences suggest that,
as Fujita [33] previously proposed for human complement,
NA accelerates the activation of rat complement through
the alternative pathway, with no participation of C1 from
the classical pathway or MBL from the lectin pathway.
Inhibition or blockade of MAC formation reduces
NA-induced ependymal damage
To assess the role of the complement system, and specif-
ically the MAC, in ependymal destruction caused by
NA, the action of this enzyme was evaluated under a
situation of partial inhibition or complete blockade of
MAC formation. For this purpose, two different in vitro
assays were developed, one using pure ependymal cell
primary cultures and the other explants from the wall of
the lateral ventricle. In both experiments, NA alone re-
sulted in damage of the ependymal cells, although damage
was greater when the complement system was also
present. Therefore, NA by itself is able to impair the epen-
dymal cells inducing morphological alterations, nuclear
pycnosis and loss of cilia motility. Cilia retraction in epen-
dymal cells after exposure to NA has been previously de-
scribed [49]. However, complement further contributes to
ependymal damage, causing more severe alterations such




Fig. 8 Quantification of ependymal epithelium disruption in different experimental conditions. a The graph shows the proportion of disrupted
ependyma relative to the total ependymal perimeter measured in histological sections. Four experimental situations were analyzed: sham-operated rats
(SHAM), NA-injected wild-type rats (WT-NA), NA-injected C5-inhibitor-treated rats (INH-NA), and NA-injected C6-deficient rats (C6-NA). Photographs show
the appearance of intact (b), damaged (c), and disrupted (d) ependymal epithelium immunostained with anti-vimentin. NA-injected WT rats display
53.5 ± 8.5 % of ependymal epithelium disruption. However, in rats with the complement system inhibited (IHN-NA and C6-NA), this proportion
decreases significantly (11.3 ± 2.5 and 7.1 ± 3.3, respectively). Bars represent the mean ± SEM. Different treatments were compared by one-way
ANOVA (F(3,11) = 25,872, P < 0.05) and Tukey’s range test. **P < 0.01. LV lateral ventricle, Ep ependyma, NP nervous parenchyma
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of ependymal cells [21, 49]. The bases of the NA cytotox-
icity on ependymal cells are unknown. The NA from C.
perfringens (Roche, cat. no. 11 585 886 001) contains less
than 0.1 % of proteases. It is well established that C. per-
fringens produces a plethora of potent toxins [62], some of
which might be included in the contaminating protease
fraction. This could represent a putative source of toxicity
for ependymal cells. Furthermore, NA is able to enhance
the cytotoxicity of some of these toxins [63]. On the other
hand, desialylation of glycoprotein receptors or surface
proteins involved in cell survival could compromise the
viability of ependymal cells.
Cells from the CNS are able to produce complement
proteins [25]. However, we discard the possibility that
the explants could be the source of complement factors
in our experiments because (i) explants are thoroughly
washed before the assay and (ii) the length of the experi-
ment is not enough for those factors to accumulate in the
culture media.
Ventricular wall explants provide a suitable in vitro
model close to the in vivo situation, as the epithelial
architecture of the ependymal is preserved. However, the
possible influence of the underlying tissue on the epen-
dymal cells cannot be ruled out. Therefore, we proceeded
to reproduce the experiment with isolated ependymal
cells. The results obtained were similar to those with ex-
plants: NA alone reduced the viability of ependymal cells
and the addition of serum as a source of complement
further reduced viability. This influence of serum was
reversed by the addition of a complement inhibitor (C5
inhibitor), confirming the complement specificity of the
observed effect and excluding the possibility that other
factors present in serum could be responsible.
An alternative experimental approach to test the role of
the complement system in the ependymal death induced
by NA consisted of the in vivo blockade of C5 activation.
C5 is pivotal in the progress of the lytic pathway of
complement, and its proteolytic activation initiates the ac-
tivation cascade that concludes with MAC assembly.
Therefore, C5 proteolysis blockade (by using a C5 in-
hibitor antibody) prevents MAC-mediated cellular lysis
[64]. The same inhibitor has been also used systemically
in other models of tissue injury, such as hemorrhagic
shock [65].
In the present work, C5 inhibitor was administered
both systemically and icv to the same animals, with the
aim of reinforcing the inhibition at the level of the ven-
tricular system. The C5-inhibited rats that were injected
with NA suffered ependymal cell disruption, albeit less
than the non-inhibited rats. The damage provoked by
NA under C5 inhibition could have several explanations:
(i) NA activates the complement system downstream of
C5 in the proteolytic cascade, this is unlikely because
in vitro experiments show NA-induced activation of
complement at the level of C3 and generates iC3b in hu-
man serum [33]; (ii) other mechanisms, independent of
complement, could account for the damage of epen-
dymal cells; and (iii) the level of inhibition achieved was
not enough to avoid the lytic action of complement, the
ongoing production of complement factors, both in the
blood and in the CSF, and the continuous circulation of
the CSF, would allow the escape of a fraction of C5 from
inhibition, enough to permit the progress of the lytic
pathway at a moderate level. This third explanation seems
the most probable because (i) serum from rats treated sys-
temically with anti-C5 had 60–70 % residual hemolytic ac-
tivity compared to that of the non-inhibited rats (our data;
not shown); (ii) published data indicates that the anti-C5
antibody used here is able to reduce the C5 activity of
serum more than 50 %, as evaluated by C5b-9-mediated
hemolytic assay [39]; and (iii) a minor amount of C5b-9
could be detected by immunohistochemistry on the
ependymal surface of the anti-C5-inhibited rats.
As exposed above, the use of functional blocking anti-
bodies against C5 relieve ependymal epithelium disrup-
tion in the NA-injected rats. This fact suggests that C5
inhibition is a suitable therapeutic strategy to prevent
ependymal loss and ventricular disorganization, which
frequently occur after CNS infections that trigger com-
plement activation.
The C6-deficient rats express a natural deletion in the
C6 gene [34, 66] that prevents C6 synthesis and forma-
tion of MAC and hence the complement-mediated cell
lysis [67, 68]. The use of this strain made it possible to
evaluate the damage induced by NA on ependymal cells
in the absence of MAC formation. Ependymal disruption
after NA injection was reduced in the C6-deficient
compared to the NA-treated wild-type rats. Since
MAC formation is completely precluded in C6 mutant
rats (and was not detected by immunohistochemistry),
our results lead us to conclude that the lytic pathway of
the complement contributes to but is not the only cause
for NA-induced ependymal damage.
Various CNS pathologies are caused by microorgan-
isms displaying the enzyme NA on their covers, such as
the flu virus [16, 69, 70], the mumps virus [13], and the
bacteria C. perfringens, which produces meningitis and
encephalitis [71]. The rats injected with NA into the
cerebral ventricles suffer ependymal cell death [40] and
a remarkable neuroinflammatory reaction [9], suggesting
an important role of this enzyme in the neurodegenerative
events occurring after microbial invasions of the CNS.
Bearing in mind the results presented here that NA can
directly activate the alternative complement pathway
[33], and the demonstrated role of the complement in
neurodegenerative processes [25, 54, 72], it may be sug-
gested that NA could be responsible, at least partially,
for the neuroinflammatory reaction observed in the icv
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NA-injected rat model [9] and, more importantly, in
the above-mentioned infectious pathologies. Pharma-
cological targeting of complement molecules could be
a strategy for reducing the damage after CNS insults
[73–75]. However, it is noteworthy that the comple-
ment system is involved in physiological processes
both during development [76–78] and in adulthood
[79]. For this reason, the design of effective thera-
peutic strategies based on the specific blockade of
complement fragments should take into account the
diverse spatiotemporal physiological functions of the
different complement fragments [73].
Conclusions
In summary, in the present work, the detection of MAC
complexes on the ependyma of NA-injected rats, to-
gether with the demonstration of in vitro activation of
C3 by NA, suggests that the complement system con-
tributes to ependymal cell damage and death observed
after NA injection into the ventricles. In vitro assays
with ventricular wall explants and isolated ependymal
cells and in vivo experiments with C6-deficient rats and
systemic and central inhibition of C5 activation demon-
strate that NA can provoke ependymal damage and cell
death even in the absence of complement activation;
however, complement activation and MAC formation
enhances and exacerbates the cellular damage and epithe-
lial disruption caused by NA. We conclude that comple-
ment participates in the ependymal cell death induced by
NA but is not the only cause.
Ethics approval and consent to participate
Animal procedures were performed according to the
European Union (86/609/EEC) and Spanish (RD 1201/
2005) legislations. Animal care and experimental proce-
dures were approved by the Animal Experimentation




Availability of data and materials
There is no new software, databases, and application/
tool available, apart from the reported in the present
article.
Abbreviations
ABC: avidin-biotin complex; BCA: bicinchoninic acid; C5-inh: C5 complement
inhibitor; CM: culture medium; CNS: central nervous system;
CSF: cerebrospinal fluid; DAB: diaminobenzidine; icv: intracerebroventricular;
MAC: membrane attack complex; MBL: mannose-binding lectin;
NA: neuraminidase; PAGE: polyacrylamide gel electrophoresis; PB: phosphate
buffer; PBS: phosphate-buffered saline; PNA: peanut (Arachis hypogaea)
agglutinin; RT: room temperature.
Competing interests
Paul P. Tamburini declare that he is a paid employee of Alexion
Pharmaceuticals Inc. and owns shares of stock in Alexion Pharmaceuticals
Inc. He is an inventor on various patents assigned to Alexion although he do
not directly benefit from them financially. The other authors have declared
that no other competing interests exist.
Authors’ contributions
MDLA, BPM, PFLL, and JMG conceived and designed the study. PGD, TRH, KJ,
and PPT performed the experiments. PGD, MDLA, PFLL, and JMG analyzed
the data. PGD, MDLA, and JMG wrote the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The Leica confocal microscope (SP5 II) was acquired with FEDER funds
of the European Union. The authors are grateful to Dr. Ruth Lewis
(Cardiff University) for her help in performing cryostat sections and
immunocytochemistry; Ms. Silvia Hernández Sánchez, Mr. José Esteban
Casares Mira and Ms. Archana Jayanthi for their valuable technical help;
and Mr. David Navas Fernández for his help with confocal microscopy.
The authors are grateful to Alexion Pharmaceuticals for the gift of the
functional blocking antibody against rat C5.
Funding
This work was carried out with fundings from Ministerio de Economía y
Competitividad (SAF2010-19087, to PFLL); Consejería de Innovación, Ciencia
y Empleo, Junta de Andalucía (P11-CVI-07637, to PFLL); and Ministerio de
Ciencia e Innovación (AP2007-03642, to PGD).
Author details
1Departamento de Biología Celular, Genética y Fisiología, IBIMA, Facultad de
Ciencias, Universidad de Málaga, Málaga 29071, Spain. 2Institute of Infection
and Immunity, School of Medicine, Cardiff University, Cardiff, UK. 3Alexion
Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, CT 06410, USA.
Received: 24 March 2016 Accepted: 9 May 2016
References
1. Bruni JE. Ependymal development, proliferation, and functions: a review.
Microsc Res Tech. 1998;41(1):2–13.
2. Kuchler S, Graff MN, Gobaille S, Vincendon G, Roche AC, Delaunoy JP, et al.
Mannose dependent tightening of the rat ependymal cell barrier. In vivo
and in vitro study using neoglycoproteins. Neurochem Int. 1994;24(1):43–55.
3. Rodriguez EM, Blazquez JL, Pastor FE, Pelaez B, Pena P, Peruzzo B, et al.
Hypothalamic tanycytes: a key component of brain-endocrine interaction.
Int Rev Cytol. 2005;247:89–164. doi:10.1016/S0074-7696(05)47003-5.
4. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Cellular composition and
three-dimensional organization of the subventricular germinal zone in the
adult mammalian brain. J Neurosci. 1997;17(13):5046–61.
5. Lim DA, Tramontin AD, Trevejo JM, Herrera DG, Garcia-Verdugo JM, Alvarez-
Buylla A. Noggin antagonizes BMP signaling to create a niche for adult
neurogenesis. Neuron. 2000;28(3):713–26.
6. Coskun V, Wu H, Blanchi B, Tsao S, Kim K, Zhao J, et al. CD133+ neural stem
cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad
Sci U S A. 2008;105(3):1026–31.
7. Paez P, Batiz LF, Roales-Bujan R, Rodriguez-Perez LM, Rodriguez S, Jimenez
AJ, et al. Patterned neuropathologic events occurring in hyh congenital
hydrocephalic mutant mice. J Neuropathol Exp Neurol. 2007;66(12):1082–92.
doi:10.1097/nen.0b013e31815c1952.
8. Jimenez AJ, Garcia-Verdugo JM, Gonzalez CA, Batiz LF, Rodriguez-Perez LM,
Paez P, et al. Disruption of the neurogenic niche in the subventricular zone
of postnatal hydrocephalic hyh mice. J Neuropathol Exp Neurol. 2009;68(9):
1006–20. doi:10.1097/NEN.0b013e3181b44a5a.
9. Granados-Duran P, Lopez-Avalos MD, Grondona JM, Gomez-Roldan Mdel C,
Cifuentes M, Perez-Martin M, et al. Neuroinflammation induced by
intracerebroventricular injection of microbial neuraminidase. Front Med.
2015;2:14. doi:10.3389/fmed.2015.00014.
10. Johnson RT, Johnson KP, Edmonds CJ. Virus-induced hydrocephalus:
development of aqueductal stenosis in hamsters after mumps infection.
Science. 1967;157(3792):1066–7.
Granados-Durán et al. Journal of Neuroinflammation  (2016) 13:115 Page 13 of 15
11. Johnson RT, Johnson KP. Hydrocephalus as a sequela of experimental
myxovirus infections. Exp Mol Pathol. 1969;10(1):68–80.
12. Margolis G, Kilham L. Hydrocephalus in hamsters, ferrets, rats, and mice
following inoculations with reovirus type I. II. Pathologic studies. Lab Invest.
1969;21(3):189–98.
13. Takano T, Mekata Y, Yamano T, Shimada M. Early ependymal changes in
experimental hydrocephalus after mumps virus inoculation in hamsters.
Acta Neuropathol. 1993;85(5):521–5.
14. Marrie RA, Wolfson C. Multiple sclerosis and Epstein-Barr virus. The Canadian
Journal of Infectious Diseases = J canadien des Mal Infect. 2002;13(2):111–8.
15. Ascherio A. Epstein-Barr virus in the development of multiple sclerosis.
Expert Rev Neurother. 2008;8(3):331–3. doi:10.1586/14737175.8.3.331.
16. Ebert T, Kotler M. Prenatal exposure to influenza and the risk of subsequent
development of schizophrenia. Isr Med Assoc J. 2005;7(1):35–8.
17. Fatemi SH, Reutiman TJ, Folsom TD, Huang H, Oishi K, Mori S, et al. Maternal
infection leads to abnormal gene regulation and brain atrophy in mouse
offspring: implications for genesis of neurodevelopmental disorders.
Schizophr Res. 2008;99(1-3):56–70. doi:10.1016/j.schres.2007.11.018.
18. Schneider-Schaulies J, Meulen V, Schneider-Schaulies S. Measles infection of
the central nervous system. J Neurovirol. 2003;9(2):247–52. doi:10.1080/
13550280390193993.
19. Rima BK, Duprex WP. Molecular mechanisms of measles virus persistence.
Virus Res. 2005;111(2):132–47. doi:10.1016/j.virusres.2005.04.005.
20. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS
injury and disease. Br J Pharmacol. 2006;147 Suppl 1:S232–40.
doi:10.1038/sj.bjp.0706400.
21. Grondona JM, Perez-Martin M, Cifuentes M, Perez J, Jimenez AJ, Perez-
Figares JM, et al. Ependymal denudation, aqueductal obliteration and
hydrocephalus after a single injection of neuraminidase into the lateral
ventricle of adult rats. J Neuropathol Exp Neurol. 1996;55(9):999–1008.
22. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides.
Annu Rev Biochem. 1985;54:631–64. doi:10.1146/annurev.bi.54.070185.
003215.
23. Muller-Eberhard HJ. The membrane attack complex of complement. Annu
Rev Immunol. 1986;4:503–28. doi:10.1146/annurev.iy.04.040186.002443.
24. Stahel PF, Morganti-Kossmann MC, Kossmann T. The role of the complement
system in traumatic brain injury. Brain Res Brain Res Rev. 1998;27(3):243–56.
25. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement
components of the innate immune system in health and disease in the
CNS. Immunopharmacology. 2000;49(1-2):171–86.
26. Casarsa C, De Luigi A, Pausa M, De Simoni MG, Tedesco F.
Intracerebroventricular injection of the terminal complement complex
causes inflammatory reaction in the rat brain. Eur J Immunol. 2003;33(5):
1260–70. doi:10.1002/eji.200323574.
27. Canova C, Neal JW, Gasque P. Expression of innate immune complement
regulators on brain epithelial cells during human bacterial meningitis. J
Neuroinflammation. 2006;3:22. doi:10.1186/1742-2094-3-22.
28. Lauf PK. Immunological and physiological characteristics of the rapid
immune hemolysis of neuraminidase-treated sheep red cells produced by
fresh guinea pig serum. J Exp Med. 1975;142(4):974–88.
29. Pangburn MK. Host recognition and target differentiation by factor H, a
regulator of the alternative pathway of complement.
Immunopharmacology. 2000;49(1-2):149–57.
30. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK. Molecular
mechanisms of target recognition in an innate immune system: interactions
among factor H, C3b, and target in the alternative pathway of human
complement. J Immunol. 2000;164(9):4742–51.
31. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement
resistance of human carcinoma cells depends on membrane regulatory
proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131(2):254–63.
32. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3
deposition by capsular polysaccharide is a virulence mechanism of type III
group B streptococci. Infect Immun. 1992;60(10):3986–93.
33. Fujita T, Ohi H, Endo M, Ohsawa I, Kanmatsuse K. The role of sialidase
in the development of hypocomplementemia in postinfectious
acute glomerulonephritis. Clin Immunol. 1999;92(1):97–102.
doi:10.1006/clim.1999.4729.
34. Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M,
et al. The membrane attack complex of the complement system is
essential for rapid wallerian degeneration. J Neurosci. 2007;27(29):7663–72.
doi:10.1523/JNEUROSCI.5623-06.2007.
35. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane
attack complex of complement causes severe demyelination associated
with acute axonal injury. J Immunol. 2002;168(1):458–65.
36. Graves IL. Heat inactivation of the neuraminidase and haemagglutinin
estimated in the agglutination-separation reactions using red blood cells
sensitized with Newcastle disease virus. Vet Res. 1999;30(4):383–92.
37. Rother RP, Arp J, Jiang J, Ge W, Faas SJ, Liu W, et al. C5 blockade with
conventional immunosuppression induces long-term graft survival in
presensitized recipients. Am J Transplant Off J Am Soc Transplant Am Soc
Transplant Surg. 2008;8(6):1129–42. doi:10.1111/j.1600-6143.2008.02222.x.
38. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Monoclonal antibodies
directed against human C5 and C8 block complement-mediated damage of
xenogeneic cells and organs. Transplantation. 1995;60(11):1284–92.
39. Costa C, Zhao L, Shen Y, Su X, Hao L, Colgan SP, et al. Role of complement
component C5 in cerebral ischemia/reperfusion injury. Brain Res. 2006;
1100(1):142–51. doi:10.1016/j.brainres.2006.05.029.
40. Grondona JM, Granados-Duran P, Fernandez-Llebrez P, Lopez-Avalos
MD. A simple method to obtain pure cultures of multiciliated
ependymal cells from adult rodents. Histochem Cell Biol. 2013;139(1):205–20.
doi:10.1007/s00418-012-1008-2.
41. Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, Van Gulik
TM. Inhibition of classical complement activation attenuates liver ischaemia
and reperfusion injury in a rat model. Clin Exp Immunol. 2006;143(1):15–23.
doi:10.1111/j.1365-2249.2005.02958.x.
42. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system
for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97.
doi:10.1038/ni.1923.
43. Podack ER, Tschoop J, Müller-Eberhard HJ. Molecular organization of C9
within the membrane attack complex of complement. Induction of circular
C9 polymerization by the C5b-8 assembly. J Exp Med. 1982;156(1):268–82.
44. Laursen SB, Thiel S, Teisner B, Holmskov U, Wang Y, Sim RB, et al. Bovine
conglutinin binds to an oligosaccharide determinant presented by iC3b, but
not by C3, C3b or C3c. Immunology. 1994;81(4):648–54.
45. Orth D, Ehrlenbach S, Brockmeyer J, Khan AB, Huber G, Karch H, et al. EspP,
a serine protease of enterohemorrhagic escherichia coli, impairs
complement activation by cleaving complement factors C3/C3b and C5.
Infect Immun. 2010;78(10):4294–301. doi:10.1128/IAI.00488-10.
46. Spiller OB, Morgan BP. Antibody-independent activation of the classical
complement pathway by cytomegalovirus-infected fibroblasts. J Infect Dis.
1998;178(6):1597–603.
47. Grondona JM, Perez-Martin M, Cifuentes M, Perez J, Estivill-Torrus G, Perez-
Figares JM, et al. Neuraminidase injected into the cerebrospinal fluid impairs
the assembly of the glycoproteins secreted by the subcommissural organ
preventing the formation of Reissner’s fiber. Histochem Cell Biol. 1998;
109(4):391–8.
48. Pérez-Martín M. Papel del epitelio ependimario en la estabilidad de los
ventrículos cerebrales y en la neurogénesis en el adulto. Doctoral Thesis.
Universidad de Málaga; 2000.
49. Gomez-Roldan MC, Perez-Martin M, Capilla-Gonzalez V, Cifuentes M,
Perez J, Garcia-Verdugo JM, et al. Neuroblast proliferation on the
surface of the adult rat striatal wall after focal ependymal loss by
intracerebroventricular injection of neuraminidase. J Comp Neurol.
2008;507(4):1571–87. doi:10.1002/cne.21618.
50. Carbonell WS, Murase SI, Horwitz AF, Mandell JW. Infiltrative microgliosis:
activation and long-distance migration of subependymal microglia
following periventricular insults. J Neuroinflammation. 2005;2(1):5.
doi:10.1186/1742-2094-2-5.
51. Tompkins WA, Seth P, Gee S, Rawls WE. Neuraminidase reversal of resistance
to lysis of herpes simplex virus-infected cells by antibody and complement.
J Immunol. 1976;116(2):489–95.
52. Barnum SR. Complement biosynthesis in the central nervous system. Crit
Rev Oral Biol Med. 1995;6(2):132–46.
53. Stahel PF, Barnum SR. Bacterial meningitis: complement gene expression in
the central nervous system. Immunopharmacology. 1997;38(1-2):65–72.
54. Morgan BP, Gasque P, Singhrao S, Piddlesden SJ. The role of
complement in disorders of the nervous system. Immunopharmacology.
1997;38(1-2):43–50.
55. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, et al.
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting
factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Immunology. 1990;71(1):1–9.
Granados-Durán et al. Journal of Neuroinflammation  (2016) 13:115 Page 14 of 15
56. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its
capacity to block incorporation of C9 into membrane C5b-9. J Immunol.
1990;144(9):3478–83.
57. Kazatchkine MD, Fearon DT, Austen KF. Human alternative
complement pathway: membrane-associated sialic acid regulates the
competition between B and beta1 H for cell-bound C3b. J Immunol.
1979;122(1):75–81.
58. Pangburn MK, Müller-Eberhard HJ. Complement C3 convertase: cell surface
restriction of beta1H control and generation of restriction on
neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978;75(5):2416–20.
59. Ninomiya H, Stewart BH, Rollins SA, Zhao J, Bothwell AL, Sims PJ.
Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to
its complement-inhibitory activity. J Biol Chem. 1992;267(12):8404–10.
60. Medicus RG, Götze O, Müller-Eberhard HJ. Alternative pathway of
complement: recruitment of precursor properdin by the labile
C3/C5 convertase and the potentiation of the pathway. J Exp Med.
1976;144(4):1076–93.
61. Rawal N, Pangburn MK. Role of the C3b-binding site on C4b-binding
protein in regulating classical pathway C5 convertase. Mol Immunol. 2007;
44(6):1105–14. doi:10.1016/j.molimm.2006.07.282.
62. Petit L, Gibert M, Popoff MR. Clostridium perfringens: toxinotype and
genotype. Trends Microbiol. 1999;7(3):104–10.
63. Li J, Sayeed S, Robertson S, Chen J, McClane BA. Sialidases affect the host
cell adherence and epsilon toxin-induced cytotoxicity of Clostridium
perfringens type D strain CN3718. PLoS Pathog. 2011;7(12):e1002429.
doi:10.1371/journal.ppat.1002429.
64. Vakeva A, Meri S. Complement activation and regulator expression after
anoxic injury of human endothelial cells. APMIS. 1998;106(12):1149–56.
65. Peckham RM, Handrigan MT, Bentley TB, Falabella MJ, Chrovian AD,
Stahl GL, et al. C5-blocking antibody reduces fluid requirements and
improves responsiveness to fluid infusion in hemorrhagic shock
managed with hypotensive resuscitation. J Appl Physiol. 2007;102(2):673–80.
doi:10.1152/japplphysiol.00917.2006.
66. Bhole D, Stahl GL. Molecular basis for complement component 6 (C6)
deficiency in rats and mice. Immunobiology. 2004;209(7):559–68.
doi:10.1016/j.imbio.2004.08.001.
67. Leenaerts PL, Stad RK, Hall BM, Van Damme BJ, Vanrenterghem Y, Daha MR.
Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol.
1994;97(3):478–82.
68. van Dixhoorn MG, Timmerman JJ, Van Gijlswijk-Janssen DJ, Muizert Y,
Verweij C, Discipio RG, et al. Characterization of complement C6 deficiency
in a PVG/c rat strain. Clin Exp Immunol. 1997;109(2):387–96.
69. Molgaard CA, Gresham L. Swine flu vaccine and amyotrophic lateral
sclerosis. JAMA. 1986;255(17):2294.
70. Takahashi M, Yamada T. A possible role of influenza a virus infection for
Parkinson’s disease. Adv Neurol. 2001;86:91–104.
71. Finsterer J, Hess B. Neuromuscular and central nervous system
manifestations of Clostridium perfringens infections. Infection. 2007;35(6):
396–405. doi:10.1007/s15010-007-6345-z.
72. Alexander JJ, Anderson AJ, Barnum SR, Stevens B, Tenner AJ. The
complement cascade: yin-yang in neuroinflammation—neuro-protection
and -degeneration. J Neurochem. 2008;107(5):1169–87. doi:10.1111/j.1471-
4159.2008.05668.x.
73. Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenberg MJ.
Complement activation in the injured central nervous system:
another dual-edged sword? J Neuroinflammation. 2012;9:137.
doi:10.1186/1742-2094-9-137.
74. Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW.
Complement in therapy and disease: regulating the complement system
with antibody-based therapeutics. Mol Immunol. 2015;67(2 Pt A):117–30.
doi:10.1016/j.molimm.2015.01.028.
75. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory
and degenerative diseases. Nat Rev Drug Discov. 2015;14(12):857–77.
doi:10.1038/nrd4657.
76. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected
role in synaptic pruning during development and disease. Annu Rev
Neurosci. 2012;35:369–89. doi:10.1146/annurev-neuro-061010-113810.
77. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR,
Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity
and complement-dependent manner. Neuron. 2012;74(4):691–705.
doi:10.1016/j.neuron.2012.03.026.
78. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S et al.
Complement and microglia mediate early synapse loss in Alzheimer mouse
models. Science. 2016. doi:10.1126/science.aad8373.
79. Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, et al.
Complement C3-deficient mice fail to display age-related hippocampal
decline. J Neurosci. 2015;35(38):13029–42. doi:10.1523/JNEUROSCI.1698-15.2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Granados-Durán et al. Journal of Neuroinflammation  (2016) 13:115 Page 15 of 15
